RVL Pharmaceuticals plc (RVLP) Financial Statements (2023 and earlier)

Company Profile

Business Address 400 CROSSING BOULEVARD
BRIDGEWATER, NJ 08807
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Receivables3,0312,13326,41243,91456,424
Inventory, net of allowances, customer advances and progress billings78483817,93421,30524,383
Inventory78483817,93421,30524,383
Other undisclosed current assets53,16056,408128,808107,41191,578
Total current assets:56,97559,379173,154172,630172,385
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization 28558 
Operating lease, right-of-use asset5121,3682,7554,983
Property, plant and equipment 700721,88230,23831,263
Intangible assets, net (including goodwill)69,74783,057166,613254,841591,245
Goodwill55,84755,847100,855100,855100,855
Intangible assets, net (excluding goodwill) 13,90027,21065,758153,986490,390
Other noncurrent assets   373563752
Other undisclosed noncurrent assets54878926,114  
Total noncurrent assets:71,53585,291197,795290,625623,260
TOTAL ASSETS:128,510144,670370,949463,255795,645
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,80216,85554,28773,748112,500
Taxes payable12 394
Accounts payable2,4073,7776,7688,49524,870
Accrued liabilities15,39513,07747,51765,25387,237
Debt1,4422,414402,1891,894
Other undisclosed current liabilities4798391,457  
Total current liabilities:19,72320,10855,78475,937114,394
Noncurrent Liabilities
Long-term debt and lease obligation18592220,965271,110266,941
Long-term debt, excluding current maturities   219,525267,950266,803
Capital lease obligations138
Finance lease, liability18 444
Liabilities, other than long-term debt2252173441,50028,041
Accounts payable and accrued liabilities 7066  1,804
Deferred tax liabilities, net26,238
Deferred income tax liabilities611513441,500
Operating lease, liability945921,4363,116
Other undisclosed noncurrent liabilities57,45147,020   
Total noncurrent liabilities:57,69447,829221,309272,610294,982
Total liabilities:77,41767,937277,093348,547409,376
Equity
Equity, attributable to parent51,09376,73393,856114,708386,269
Common stock992833625518525
Additional paid in capital619,323591,730548,070489,440489,950
Accumulated other comprehensive income (loss)  1,700(2,229)(2,229)(1,846)
Accumulated deficit(569,222)(517,530)(452,610)(373,021)(102,360)
Total equity:51,09376,73393,856114,708386,269
TOTAL LIABILITIES AND EQUITY:128,510144,670370,949463,255795,645

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues49,72117,501177,884240,031263,701
Cost of revenue
(Cost of Goods and Services Sold)
(9,456)(3,618)(74,480)(111,630)(135,014)
Gross profit:40,26513,883103,404128,401128,687
Operating expenses(99,255)(102,273)(173,840)(409,096)(227,225)
Other undisclosed operating income  5,636   
Operating loss:(58,990)(82,754)(70,436)(280,695)(98,538)
Nonoperating income (expense)6,262(1,333)546884(20,126)
Loss, foreign currency transaction, before tax  (2,229)   
Interest and debt expense(3,110)(3,036)(14,396)(18,211)(876)
Loss from continuing operations before equity method investments, income taxes:(55,838)(87,123)(84,286)(298,022)(119,540)
Other undisclosed income (loss) from continuing operations before income taxes4,1264,589  876
Loss from continuing operations before income taxes:(51,712)(82,534)(84,286)(298,022)(118,664)
Income tax benefit  3154,69727,1219,268
Loss from continuing operations:(51,712)(82,219)(79,589)(270,901)(109,396)
Loss before gain (loss) on sale of properties:(68,352)(79,589)(270,901)(109,396)
Income from discontinued operations  13,867   
Other undisclosed net income203,432   
Net loss available to common stockholders, diluted:(51,692)(64,920)(79,589)(270,901)(109,396)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(51,692)(64,920)(79,589)(270,901)(109,396)
Comprehensive loss:(51,692)(64,920)(79,589)(270,901)(109,396)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (1,700)3,929 (383)(1,213)
Comprehensive loss, net of tax, attributable to parent:(53,392)(60,991)(79,589)(271,284)(110,609)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: